Congratulations to Onyx Pharmaceuticals!

Accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection

Anti-cancer drug gets acellerated FDA approval

Congratulations to Onyx Pharmaceuticals on the accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection, a proteasome inhibitor for the treatment of patients with multiple myeloma. Read the official press release.

For some analysts take on business ramifications, see:,,,

Disclaimer:  CDD’s Barry Bunin was on one of the early patents for carfilzomib:  Smyth, M. S.; Laidig, G. J; Borchardt, R. T.; Bunin, B. A.; Crews, C. M.; Musser, J. H.; Schneekloth, J. S.; Chabala, J. C.  Compounds for Enzyme Inhibition.  Patent No. US 2005/0245434 A1; issued 3 Nov 2005 (Proteolix, Inc).  Proteolix was acquired by Onyx Pharmaceuticals: